Pictet Asset Management Holding SA lowered its holdings in Insulet Corporation (NASDAQ:PODD – Free Report) by 80.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,611 shares of the medical instruments supplier’s stock after selling 60,825 shares during the period. Pictet Asset Management Holding SA’s holdings in Insulet were worth $1,906,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State of Wyoming increased its position in shares of Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after acquiring an additional 73 shares during the period. Basecamp Wealth Advisors LLC grew its position in shares of Insulet by 48.3% during the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 102 shares in the last quarter. Elevation Wealth Partners LLC raised its holdings in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 104 shares in the last quarter. Pinnacle Associates Ltd. grew its holdings in Insulet by 6.1% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,855 shares of the medical instruments supplier’s stock worth $242,000 after acquiring an additional 107 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC increased its position in shares of Insulet by 4.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 3,194 shares of the medical instruments supplier’s stock valued at $429,000 after purchasing an additional 134 shares during the last quarter.
Wall Street Analyst Weigh In
PODD has been the topic of several research analyst reports. Stifel Nicolaus cut their target price on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Sanford C. Bernstein increased their price target on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Truist Financial reaffirmed a “hold” rating and set a $160.00 price objective (up from $153.00) on shares of Insulet in a research note on Monday, November 9th. Royal Bank Of Canada upped their price target on Insulet from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Robert W. Baird set a $175.00 price target on shares of Insulet in a report on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $185.67.
Get Our Latest Stock Analysis on PODD
Insulet Stock Performance
Shares of PODD stock opened at $152.48 on Monday. The stock has a market cap of $10.58 billion, a P/E ratio of 24.83, a P/E/G ratio of 1.16 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The business has a fifty day simple moving average of $142.14 and a 200-day simple moving average of $173.54.
Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. During the same period in the prior year, the company earned $1.24 EPS. The firm’s revenue was up 19.2% on a year-over-year basis. On average, analysts forecast that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.
Insulet Profile
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
See Also
- Five stocks we like better than Insulet
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
